Search

Displaying results 3841 - 3850 of 6074 in total
  1. Drug

    Rilotumumab

    go.drugbank.com/drugs/DB11972
    Investigational

    Rilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.

  2. Drug

    SRT-2104

    go.drugbank.com/drugs/DB12186
    Investigational

    SRT2104 has been investigated for the basic science and treatment of Sepsis, PSORIASIS, Atrophy, Muscular, and Diabetes Mellitus, Type 2.

  3. Drug

    Acapatamab

    go.drugbank.com/drugs/DB18838
    Investigational

    Acapatamab is under investigation in clinical trial NCT04631601 (Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (Mcrpc)).

  4. Drug

    Zeluvalimab

    go.drugbank.com/drugs/DB18868
    Investigational

    Zeluvalimab is under investigation in clinical trial NCT04631601 (Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (Mcrpc)).

  5. Drug

    Aglatimagene besadenovec

    go.drugbank.com/drugs/DB15074
    Investigational

    Aglatimagene besadenovec is under investigation in clinical trial NCT00638612 (AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)).

  6. Drug

    Caficrestat

    go.drugbank.com/drugs/DB15121
    Investigational

    AT-001 is under investigation in clinical trial NCT03062384 (AT-001 for Long-term Preservation of Brain Health in Aging).

  7. Drug

    Bfpet F-18

    go.drugbank.com/drugs/DB15424
    Investigational

    Bfpet F-18 is under investigation in clinical trial NCT03265431 (Evaluation of PET/MR in Patients Selected for Ablation Therapy).

  8. Drug

    PLT012

    go.drugbank.com/drugs/DB23610
    Investigational

    PLT012 is a humanized anti-CD36 antibody developed by Pilatus Biosciences for treating liver cancer and intrahepatic bile duct cancer.

  9. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. … Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases.

  10. Drug

    Enzastaurin

    go.drugbank.com/drugs/DB06486
    Investigational

    Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of